MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BridgeBio Oncology Therapeutics, Inc. - Common Stock (NQ:BBOT)

8.415 -0.405 (-4.59%)
Streaming Delayed Price Updated: 12:44 PM EDT, Jul 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about BridgeBio Oncology Therapeutics, Inc. - Common Stock

News headline image
BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress
From TheRas, Inc. (d/b/a BBOT)
Via GlobeNewswire
News headline image
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From TheRas, Inc. (d/b/a BBOT)
Via GlobeNewswire
News headline image
BBOT Presents Preclinical Data Demonstrating pan-KRAS Inhibitor BBO-11818 Has Robust Anti-Tumor Activity in KRAS-Mutant Preclinical Models at the AACR Annual Meeting 2026
From TheRas, Inc. (d/b/a BBOT)
Via GlobeNewswire
News headline image
BBOT Announces the Appointment of Pedro J. Beltran, PhD, as Chief Executive Officer, Idan Elmelech as Chief Operating Officer, and Neil Kumar, PhD, as Executive Chairman
From TheRas, Inc. (d/b/a BBOT)
Via GlobeNewswire
News headline image
BBOT Presents Preclinical Data Showing RAS:PI3Kα Breaker BBO-10203 Inhibits PI3Kα/AKT Signaling in HER2AMP Models at the AACR Annual Meeting 2026
From TheRas, Inc. (d/b/a BBOT)
Via GlobeNewswire
News headline image
BBOT Granted U.S. FDA Fast Track Designation for BBO-11818 for the Treatment of Adult Patients with Advanced KRAS-Mutant Pancreatic Ductal Adenocarcinoma
From TheRas, Inc. (d/b/a BBOT)
Via GlobeNewswire
News headline image
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From TheRas, Inc. (d/b/a BBOT)
Via GlobeNewswire
News headline image
BBOT Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026
From TheRas, Inc. (d/b/a BBOT)
Via GlobeNewswire
News headline image
BBOT Announces Publication in Cancer Discovery Highlighting Preclinical Data Demonstrating BBO-11818 is a Potent and Selective panKRAS Inhibitor
From TheRas, Inc. (d/b/a BBOT)
Via GlobeNewswire
News headline image
BBOT Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress
From TheRas, Inc. (d/b/a BBOT)
Via GlobeNewswire
News headline image
BBOT to Participate in Upcoming Investor Healthcare Conferences
From TheRas, Inc. (d/b/a BBOT)
Via GlobeNewswire
News headline image
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From TheRas, Inc. (d/b/a BBOT)
Via GlobeNewswire
News headline image
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From TheRas, Inc. (d/b/a BBOT)
Via GlobeNewswire
News headline image
BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3Kα Pipeline Programs
From TheRas, Inc. (d/b/a BBOT)
Via GlobeNewswire
News headline image
BBOT to Present at the 44th Annual J.P. Morgan Healthcare Conference
From TheRas, Inc. (d/b/a BBOT)
Via GlobeNewswire
News headline image
BBOT Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From TheRas, Inc. (d/b/a BBOT)
Via GlobeNewswire
News headline image
BBOT Announces Late-Breaking Preclinical Data on BBO-10203, a First-in-Class RAS:PI3Kα Breaker, at the San Antonio Breast Cancer Symposium (SABCS)
From TheRas, Inc. (d/b/a BBOT)
Via GlobeNewswire
News headline image
BBOT to Participate in Upcoming December Investor Healthcare Conferences
From TheRas, Inc. (d/b/a BBOT)
Via GlobeNewswire
News headline image
BBOT Reports Third Quarter 2025 Financial Results and Update on Corporate Progress
From TheRas, Inc. (d/b/a BBOT)
Via GlobeNewswire
News headline image
BBOT to Participate in the Jefferies Global Healthcare Conference in London
From TheRas, Inc. (d/b/a BBOT)
Via GlobeNewswire
News headline image
BBOT Announces Poster Presentations at the San Antonio Breast Cancer Symposium (SABCS)
From TheRas, Inc. (d/b/a BBOT)
Via GlobeNewswire
News headline image
Preclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3Kα Breaker That Inhibits KRAS-Mutant Tumor Growth without Inducing
From TheRas, Inc. (d/b/a BBOT)
Via GlobeNewswire
News headline image
BBOT Presents Preclinical Data Demonstrating Potential of BBO-11818 as a Potent panKRAS Inhibitor at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From TheRas, Inc. (d/b/a BBOT)
Via GlobeNewswire
News headline image
BBOT Announces Poster Presentations at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From TheRas, Inc. (d/b/a BBOT)
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story